MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction

Neoplasia. 2020 Aug;22(8):311-321. doi: 10.1016/j.neo.2020.05.003. Epub 2020 Jun 16.

Abstract

The detection of specific alterations by genetic analyses has been included in the diagnostic criterions of the World Health Organization's classification of soft tissues tumors since 2013. The presence of a SS18 rearrangement is pathognomonic of synovial sarcoma (SS). MDM2 amplification is strongly correlated to well-differentiated or dedifferentiated liposarcoma (DDLPS) in the context of sarcoma. We identified one case of poorly differentiated sarcoma harboring both SS18-SSX2 fusion and MDM2 amplification. The review of the literature showed high discrepancies, concerning the incidence of MDM2 amplification in SS: from 1.4% up to 40%. Our goal was to precisely determine the specific clinico-pathological features of this case and to estimate the frequency and characteristics of the association of SS18-SSX fusion/MDM2 amplification in sarcomas. We performed a retrospective and prospective study in 96 sarcomas, (56 SS and 40 DDLPS), using FISH and/or array-CGH to detect MDM2 amplification and SS18 rearrangement. None of the 96 cases presented both genetic alterations. Among the SS, only the index case (1/57: 1.7 %) presented the double anomaly. We concluded that MDM2 amplification in SS is a very rare event. The final diagnosis of the index case was a SS with SS18-SSX2 and MDM2 amplification as a secondary alteration. If the detection of MDM2 amplification is performed first in a poorly differentiated sarcoma, that may lead to not search other anomalies such as SS18 rearrangement and therefore to an erroneous diagnosis. This observation emphasizes the strong complementarity between histomorphology, immunohistochemistry and molecular studies in sarcoma diagnosis.

Keywords: Amplification; Diagnosis; Liposarcoma; MDM2; Synovial sarcoma.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Follow-Up Studies
  • Gene Amplification*
  • Humans
  • Male
  • Middle Aged
  • Oncogene Proteins, Fusion / genetics*
  • Prognosis
  • Prospective Studies
  • Proto-Oncogene Proteins c-mdm2 / genetics*
  • Retrospective Studies
  • Sarcoma, Synovial / genetics
  • Sarcoma, Synovial / pathology*
  • Young Adult

Substances

  • Oncogene Proteins, Fusion
  • SS18-SSX1 fusion protein
  • SYT-SSX fusion protein
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2